106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Send us a text

In this insightful episode, Technical Development Leader at Flagship Pioneering Oliver Kraemer reveals why developing Advanced Therapy Medicinal Products (ATMPs) require a fundamental shift in thinking from traditional biologics development.

Drawing from his extensive experience across Boehringer Ingelheim, Sanofi, and BMS, Kraemer challenges conventional wisdom about process development timing and demonstrates why early integration of process considerations is crucial for ATMP success.

You will learn:

• Rethink Development Timing: Learn why incorporating process development earlier in ATMP programs dramatically reduces failure rates and prevents costly repetition
• Master Complexity: Understand the unique challenges of cell therapy development, including biological fitness and the critical interplay between cell lines, media, and processes
• Navigate Cost Implications: Discover strategies for managing the unexpectedly high development costs of ATMPs and making informed early decisions that impact commercial success

Ready to transform your approach to ATMP development? Join us for this must-listen episode as we demystify the path from bench to bedside in cell and gene therapy.

Connect with Oliver Kraemer:

LinkedIn: https://www.linkedin.com/in/oliver-kraemer

Next Steps:

Overwhelmed by complex CGT development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving cell and gene therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment